Literature DB >> 23478418

Anaemia: The safety and efficacy of peginesatide in patients with CKD.

Kai-Uwe Eckardt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23478418     DOI： 10.1038/nrneph.2013.42

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

Authors:  Richard B Stead; John Lambert; Dawie Wessels; Julie S Iwashita; Kerstin K Leuther; Kathryn W Woodburn; Peter J Schatz; Douglas M Okamoto; Robert Naso; Anne-Marie Duliege
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

2.  Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients.

Authors:  Iain C Macdougall; Andrzej Wiecek; Beatriz Tucker; Magdi Yaqoob; Ashraf Mikhail; Michal Nowicki; Iain MacPhee; Michal Mysliwiec; Olgierd Smolenski; Władysław Sułowicz; Martha Mayo; Carol Francisco; Krishna R Polu; Peter J Schatz; Anne-Marie Duliege
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-22       Impact factor: 8.237

3.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

4.  Small peptides as potent mimetics of the protein hormone erythropoietin.

Authors:  N C Wrighton; F X Farrell; R Chang; A K Kashyap; F P Barbone; L S Mulcahy; D L Johnson; R W Barrett; L K Jolliffe; W J Dower
Journal:  Science       Date:  1996-07-26       Impact factor: 47.728

5.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

Authors:  A Besarab; W K Bolton; J K Browne; J C Egrie; A R Nissenson; D M Okamoto; S J Schwab; D A Goodkin
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

6.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

7.  Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.

Authors:  Iain C Macdougall; Robert Provenzano; Amit Sharma; Bruce S Spinowitz; Rebecca J Schmidt; Pablo E Pergola; Raja I Zabaneh; Sandra Tong-Starksen; Martha R Mayo; Hong Tang; Krishna R Polu; Anne-Marie Duliege; Steven Fishbane
Journal:  N Engl J Med       Date:  2013-01-24       Impact factor: 91.245

8.  Peginesatide in patients with anemia undergoing hemodialysis.

Authors:  Steven Fishbane; Brigitte Schiller; Francesco Locatelli; Adrian C Covic; Robert Provenzano; Andrzej Wiecek; Nathan W Levin; Mark Kaplan; Iain C Macdougall; Carol Francisco; Martha R Mayo; Krishna R Polu; Anne-Marie Duliege; Anatole Besarab
Journal:  N Engl J Med       Date:  2013-01-24       Impact factor: 91.245

9.  A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.

Authors:  Iain C Macdougall; Jerome Rossert; Nicole Casadevall; Richard B Stead; Anne-Marie Duliege; Marc Froissart; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2009-11-05       Impact factor: 91.245
  9 in total
  4 in total

Review 1.  Watching the gorilla and questioning delivery dogma.

Authors:  Thomas J Anchordoquy; Dmitri Simberg
Journal:  J Control Release       Date:  2017-07-14       Impact factor: 9.776

Review 2.  Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management.

Authors:  Nicoletta Luxi; Alexia Giovanazzi; Alessandra Arcolaci; Patrizia Bonadonna; Maria Angiola Crivellaro; Paola Maria Cutroneo; Carmen Ferrajolo; Fabiana Furci; Lucia Guidolin; Ugo Moretti; Elisa Olivieri; Giuliana Petrelli; Giovanna Zanoni; Gianenrico Senna; Gianluca Trifirò
Journal:  BioDrugs       Date:  2022-06-13       Impact factor: 7.744

Review 3.  HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.

Authors:  Patrick H Maxwell; Kai-Uwe Eckardt
Journal:  Nat Rev Nephrol       Date:  2015-12-14       Impact factor: 28.314

Review 4.  Revisiting the outstanding questions in cancer nanomedicine with a future outlook.

Authors:  M S Sudheesh; K Pavithran; Sabitha M
Journal:  Nanoscale Adv       Date:  2021-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.